Table 2.
Patients analyzed in antigen presentation assays.
| Disease | Code | Age range* | ERT/SRT |
|---|---|---|---|
| Fabry | 1F | 51–55 | Yes |
| 2F | 36–40 | Yes | |
| 3F | 61–65 | Yes | |
| 4F | 51–55 | Yes | |
| 5F | 46–50 | No | |
| 6F | 36–40 | No | |
| 7F | 16–20 | No | |
| 8F | 21–25 | No | |
| Gaucher | 1G | 1–5 | Yes |
| 2G | 11–15 | Yes | |
| 3G | 26–30 | Yes | |
| 4G | 11–15 | Yes | |
| 5G | 51–55 | No | |
| 6G | 46–50 | Yes | |
| 7G | 76–80 | Yes | |
| 8G | 66–70 | Yes | |
| 9G | 26–30 | No | |
| 10G | 36–40 | Yes | |
| 11G | 71–75 | Yes | |
| 12G | 71–75 | Yes | |
| 13G | 60–65 | Yes | |
| 14G | 6–10 | Yes | |
| 15G | 21–25 | Yes | |
| 16G | 21–25 | Yes | |
| NPC | 1N | 1–5 | Yes |
| 2N | 16–20 | Yes | |
| 3N | 16–20 | Yes | |
| 4N | 6–10 | Yes | |
| 5N | 21–25 | Yes | |
| 6N | 26–30 | Yes | |
| 7N | 31–35 | Yes | |
| 8N | 11–15 | Yes | |
| MPS-VI | 1M | 16–20 | Yes |
| 2M | 16–20 | Yes | |
| 3M | 26–30 | Yes | |
| 4M | 11–15 | Yes | |
| 5M | 16–20 | Yes | |
| 6M | 16–20 | Yes | |
| 7M | 5–10 | Yes |
Patient age was within this interval at the moment of the study.